Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

Peer Review reports

Original Submission
23 Dec 2015	Submitted	Original manuscript
9 Mar 2016	Reviewed	Reviewer Report - Scott C. Woller
31 Aug 2016	Author responded	Author comments - Tereza Lanitis
Resubmission - Version 2
31 Aug 2016	Submitted	Manuscript version 2
16 Nov 2016	Author responded	Author comments - Tereza Lanitis
Resubmission - Version 3
16 Nov 2016	Submitted	Manuscript version 3
Publishing
10 Jan 2017	Editorially accepted
23 Jan 2017	Article published	10.1186/s12913-017-1995-8

Back to article page